MRX34 as treatment for patients with unresectable liver cancer or metastatic cancer with liver involvement
This Phase I study is designed to evaluate the safety of MRX34 in patients with primary liver cancer or those with liver metastasis from other cancers.
The primary objective is to identify the side effects of MRX34.
The study will enroll approximately 48 patients at two cancer centers in Texas.
In addition to other conditions for enrollment, eligible patients have liver cancer or advanced metastatic cancer with liver metastasis that cannot be removed surgically and are otherwise in good health.
Patients who have a history of infection including hepatitis, bleeding problems, central nervous system involvement, or require anticoagulant therapy may not be eligible to enroll.
To enroll or if you have questions about participation